First-Line Immune Combination Therapies for Nonclear Cell Versus Clear Cell Metastatic Renal Cell Carcinoma:...

Area of Science:

• Oncology
• Immunotherapy
• Renal Cell Carcinoma Research

Background:

• Metastatic renal cell carcinoma (mRCC) treatment has evolved with immune combination therapies.
• Clear cell (ccmRCC) and non-clear cell (nccmRCC) subtypes represent distinct disease entities.
• Comparing treatment outcomes between ccmRCC and nccmRCC is crucial for personalized medicine.

Purpose of the Study:

• To compare treatment outcomes (overall survival and progression-free survival) of ccmRCC versus nccmRCC patients.
• To evaluate the efficacy of first-line immune combination therapies in different mRCC subtypes.
• To identify potential differences in response to immunotherapy based on RCC histology.

Main Methods:

• Retrospective analysis of a multi-institutional database (eight tertiary-care centers).
• Inclusion of mRCC patients treated with first-line immune combination therapies (11/2017-12/2022).
• Log-rank analysis and multivariable Cox regression to compare OS and PFS, adjusting for covariates (age, sex, risk groups, ECOG status, sarcomatoid feature).

Main Results:

• The study included 289 mRCC patients; 39 (13%) had nccmRCC.
• Median overall survival (OS) was 37 months for ccmRCC vs. not reached for nccmRCC (P = .6).
• Median progression-free survival (PFS) was 13 months for ccmRCC vs. 15 months for nccmRCC (P = .9).
• Multivariable analysis showed nccmRCC was not an independent predictor of higher mortality (HR: 1.23; P = .6) or progression (HR: 1.0; P = 1.0).

Conclusions:

• First-line immune combination therapy demonstrated similar OS and PFS in both ccmRCC and nccmRCC patients.
• Histological subtype (ccmRCC vs. nccmRCC) did not significantly impact outcomes in this real-world setting.
• Further prospective clinical trials are warranted to specifically investigate treatment strategies for nccmRCC patients.